Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (0.5 mg to 800 mg) of BI 10773 as Tablets Administered to Healthy Male Subjects. A Randomised Placebo-controlled (Within-dose Groups) and Double-blind Trial.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 28 Jun 2014 New trial record